S&P: DaVita unaffected

Standard & Poor's said the ratings and outlook on DaVita Inc. (BB-/stable/--) would not be affected after the company received a subpoena from the U.S. Department of Justice, United States Attorney's Office for the Eastern District of Missouri on March 4.

S&P said the subpoena covers a period from Dec. 1, 1996 to the present, and relates to DaVita's medical director compensation, its joint ventures and de novo facilities and pharmaceutical issues. No proceedings have been initiated against the company as yet.

While the size and likelihood of any related liabilities stemming from this investigation are uncertain, S&P said it believes that if DaVita were to settle in the near term, it would be under favorable circumstances.

Any unfavorable outcomes would likely be in the distant future, according to S&P, when the company's financial profile might be stronger than it is currently.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.